Table 4. Overall survival by VEGFA genotype in patients with resected HCC.
| Genotype | Cases, n | Deaths, n | MST (Mo) | 95% CI (Mo) | P value |
|---|---|---|---|---|---|
| VEGF 634G/C* | 0.385 | ||||
| GG | 79 | 23 | 53 | 43.4–62.6 | |
| GC/CC | 143 | 29 | 51 | 48.4–54.6 | |
| VEGF 936 C/T* | 0.740 | ||||
| CC | 168 | 37 | 51 | 48.3–54.0 | |
| CT/TT | 54 | 15 | 50 | 46.5–53.4 | |
| VEGF 1612G/A* | 0.213 | ||||
| GG | 125 | 34 | 50 | 43.9–56.1 | |
| GA/AA | 97 | 18 | 53 | 49.8–56.8 | |
| VEGF 2578C/A* | 0.001 | ||||
| CC | 129 | 38 | 48 | 41.7–54.3 | |
| CA/AA | 93 | 14 | 55 | 51.7–58.4 |
HCC, hepatocelluar carcinoma; MST, median survival time; Mo, months; CI, confidence interval.
*
Mean survival time was provided when MST could not be calculated.